BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 15897907)

  • 1. Identification of molecular apocrine breast tumours by microarray analysis.
    Farmer P; Bonnefoi H; Becette V; Tubiana-Hulin M; Fumoleau P; Larsimont D; Macgrogan G; Bergh J; Cameron D; Goldstein D; Duss S; Nicoulaz AL; Brisken C; Fiche M; Delorenzi M; Iggo R
    Oncogene; 2005 Jul; 24(29):4660-71. PubMed ID: 15897907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
    J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours.
    Richard E; Grellety T; Velasco V; MacGrogan G; Bonnefoi H; Iggo R
    J Pathol; 2016 Nov; 240(3):256-261. PubMed ID: 27447842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours.
    Iggo RD
    Breast Cancer Res; 2011; 13(6):318. PubMed ID: 22188611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1.
    Robinson JL; Macarthur S; Ross-Innes CS; Tilley WD; Neal DE; Mills IG; Carroll JS
    EMBO J; 2011 Jun; 30(15):3019-27. PubMed ID: 21701558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
    Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
    Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
    Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.
    Chia KM; Liu J; Francis GD; Naderi A
    Neoplasia; 2011 Feb; 13(2):154-66. PubMed ID: 21403841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
    D'Arcy C; Quinn CM
    J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype.
    Titloye NA; Foster A; Omoniyi-Esan GO; Komolafe AO; Daramola AO; Adeoye OA; Adisa AO; Manoharan A; Pathak D; D'Cruz MN; Alizadeh Y; Lewis PD; Shaaban AM
    Pathobiology; 2016; 83(1):24-32. PubMed ID: 26730581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.
    Naderi A; Meyer M
    Breast Cancer Res; 2012 Jul; 14(4):R111. PubMed ID: 22817771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
    Niemeier LA; Dabbs DJ; Beriwal S; Striebel JM; Bhargava R
    Mod Pathol; 2010 Feb; 23(2):205-12. PubMed ID: 19898421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IPH-926 lobular breast cancer cells are triple-negative but their microarray profile uncovers a luminal subtype.
    Christgen M; Geffers R; Kreipe H; Lehmann U
    Cancer Sci; 2013 Dec; 104(12):1726-30. PubMed ID: 24344720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.
    Moore NL; Buchanan G; Harris JM; Selth LA; Bianco-Miotto T; Hanson AR; Birrell SN; Butler LM; Hickey TE; Tilley WD
    Endocr Relat Cancer; 2012 Aug; 19(4):599-613. PubMed ID: 22719059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
    Gatalica Z
    Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
    Collins LC; Cole KS; Marotti JD; Hu R; Schnitt SJ; Tamimi RM
    Mod Pathol; 2011 Jul; 24(7):924-31. PubMed ID: 21552212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.
    Lehmann-Che J; Hamy AS; Porcher R; Barritault M; Bouhidel F; Habuellelah H; Leman-Detours S; de Roquancourt A; Cahen-Doidy L; Bourstyn E; de Cremoux P; de Bazelaire C; Albiter M; Giacchetti S; Cuvier C; Janin A; Espié M; de Thé H; Bertheau P
    Breast Cancer Res; 2013 May; 15(3):R37. PubMed ID: 23663520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors.
    Selim AG; Wells CA
    J Clin Pathol; 1999 Nov; 52(11):838-41. PubMed ID: 10690175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
    Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
    Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.